About Hopewell Therapeutics
Hopewell Therapeutics is a private company based in Woburn, Massachusetts. It has reported $25,915,599 raised in five offerings on Form D since December 2020.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2025 | Sep 17, 2025 | $2,499,999of $3.4M target | 2 | $1.2M | EquityRule 506(b) | Form D ↗ |
| May 19, 2023 | Jun 2, 2023amended May 17, 2024 | $7,800,004of $10.0M target | 8 | $975K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jan 18, 2022 | Feb 2, 2022 | $7,108,361fully sold | 4 | $1.7M | EquityRule 506(b) | Form D ↗ |
| Sep 24, 2021 | Oct 8, 2021 | $8,007,235fully sold | 2 | $4.0M | EquityRule 506(b) | Form D ↗ |
| Dec 7, 2020 | Dec 21, 2020 | $500,000fully sold | 1 | $500K | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, five offerings | $25,915,599 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Hopewell Therapeutics's Form D filed Sep 17, 2025.
NS
Nan Shen
Director
QX
Qiaobing Xu
President and director
TI
Thomas Hennessey, III
Director
XJ
Xutian Jing
Director
XF
Xiaowen Femg
Director
CP
C. Paschall
Director
Earlier filings also listed Jake Xia (director, last listed May 2024) and Howard Rosen (director, last listed Feb 2022).